{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:01:38Z","timestamp":1787029298306,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Science, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Pangenotypic direct-acting antivirals (pDAAs) have transformed hepatitis C virus (HCV) treatment. In Italy, sofosbuvir\/velpatasvir (SOF\/VEL) and glecaprevir\/pibrentasvir (GLE\/PIB) are available. While both show similar efficacy, differences in patient profiles and potential drug\u2013drug interactions (DDIs) may influence treatment choice. This study examined factors affecting pDAA selection and potential prescribing gaps. Using administrative databases (2018\u20132023) covering 3.7 million citizens, HCV patients were divided into SOF\/VEL and GLE\/PIB cohorts and compared by demographic, clinical, and therapeutic data. Among 5565 patients, 2837 (51%) received SOF\/VEL and 2728 (49%) received GLE\/PIB. SOF\/VEL patients were older (60.8 vs. 57.6 years, p &lt; 0.001) and had more comorbidities: diabetes (24% vs. 17%), mental disorders (22% vs. 14%), cancer (14% vs. 9%), and cardiovascular disease (31% vs. 22%). Hospitalization rates were higher (19% vs. 13%), as were exemption codes for chronic hepatitis (58% vs. 50%) and hypertension (32% vs. 23%). Polypharmacy was more common with SOF\/VEL; 25% used \u226510 non-pDAA drugs (vs. 17%), and mean medications per patient were higher (6.3 \u00b1 5.6 vs. 4.9 \u00b1 5.2). SOF\/VEL was often used for older, frailer patients, likely due to a more favourable DDI profile. These prescribing trends highlight the importance of tailoring pDAA choice to patient comorbidity profiles, ensuring appropriate and individualized HCV treatment.<\/jats:p>","DOI":"10.3390\/pathogens14111177","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:58:42Z","timestamp":1763459922000},"page":"1177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-1412","authenticated-orcid":false,"given":"Nicola","family":"Pugliese","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy"},{"name":"Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Conti","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna, Ospedale degli Infermi di Faenza, 48018 Faenza, FC, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-2414","authenticated-orcid":false,"given":"Valerio","family":"Rosato","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Medicina Interna ed Epatologia, Ospedale Evangelico Villa Betania, 80147 Napoli, NA, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-1134","authenticated-orcid":false,"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[{"name":"UOS Medicina Clinica ed Epatologia, Policlinico Universitario Campus Bio-Medico, 00128 Roma, RM, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-6508","authenticated-orcid":false,"given":"Stefano","family":"Gitto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, 50141 Firenze, FI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Riglietta","sequence":"additional","affiliation":[{"name":"UOC Dipendenze, ASST Papa Giovanni XXIII, 24127 Bergamo, BG, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6498-4712","authenticated-orcid":false,"given":"Francesca","family":"Frigerio","sequence":"additional","affiliation":[{"name":"Gilead Sciences, 20146 Milano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-490X","authenticated-orcid":false,"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, BO, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-2022","authenticated-orcid":false,"given":"Chiara","family":"Veronesi","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, BO, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-9532","authenticated-orcid":false,"given":"Maria","family":"Cappuccilli","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, BO, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-6659","authenticated-orcid":false,"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research, 40137 Bologna, BO, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-3555","authenticated-orcid":false,"given":"Alessandra","family":"Mangia","sequence":"additional","affiliation":[{"name":"UOS Epatologia, Istituto di Ricovero e Cura (IRCCS) \u201cCasa Sollievo della Sofferenza\u201d, 71013 San Giovanni Rotondo, FG, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-224X","authenticated-orcid":false,"given":"Loreta A.","family":"Kondili","sequence":"additional","affiliation":[{"name":"Center for Global Health, Istituto Superiore di Sanit\u00e0, 00161 Rome, RM, Italy"},{"name":"Internal Medicine, UniCamillus International Medical Universityof Health Sciences, 00131 Rome, RM, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, July 21). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.23736\/S0026-4806.21.07280-3","article-title":"Viral Hepatitis ISS-UNICZ study group Changing epidemiology of hepatitis C in Italy: A population-based survey in a historically high endemic area","volume":"114","author":"Spada","year":"2023","journal-title":"Minerva Medica"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nevola, R., Messina, V., Marrone, A., Coppola, N., Rescigno, C., Esposito, V., Sangiovanni, V., Claar, E., Pisaturo, M., and Fusco, F.M. (2022). Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 11.","DOI":"10.3390\/biology11040609"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMp1400986","article-title":"Curing chronic hepatitis C\u2014The arc of a medical triumph","volume":"370","author":"Chung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/emmm.201303131","article-title":"Emerging therapies for the treatment of hepatitis C","volume":"6","author":"Lange","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756283X15587481","article-title":"The changing landscape of hepatitis C virus therapy: Focus on interferon-free treatment","volume":"8","author":"Lam","year":"2015","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: The toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_10","first-page":"175628481881235","article-title":"Sofosbuvir, velpatasvir and voxilaprevir: A new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?","volume":"11","author":"Pietri","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhuang, L., Li, J., Zhang, Y., Ji, S., and Xing, H. (2025). Real-world effectiveness of sofosbuvir\/velpatasvir, glecaprevir\/pibrentasvir, and sofosbuvir\/velpatasvir\/voxilaprevir against genotype 3 hepatitis C virus infection: A systematic review and meta-analysis. Front. Gastroenterol., 4.","DOI":"10.3389\/fgstr.2025.1511150"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chang, K.-C., Tung, S.-Y., Wei, K.-L., Shen, C.-H., Hsieh, Y.-Y., Chen, W.-M., Chen, Y.-H., Chen, C.-H., Yen, C.-W., and Xu, H.-W. (2021). Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93095-x"},{"key":"ref_14","first-page":"e17237","article-title":"Sofosbuvir\/velpatasvir: A promising treatment for chronic hepatitis C virus infection","volume":"13","author":"Ahmed","year":"2021","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100237","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_16","first-page":"125","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection","volume":"9","author":"Liu","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jvh.13814","article-title":"The tolerability of sofosbuvir\/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis","volume":"30","author":"Jacobson","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1136\/ejhpharm-2019-002060","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir \u00b1 ribavirin vs glecaprevir\/pibrentasvir in genotype 3 hepatitis C virus infected patients","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Santander Ballest\u00edn, S., G\u00f3mez Mart\u00edn, D., Lorente P\u00e9rez, S., and Luesma Bartolom\u00e9, M.J. (2021). Hepatitis C: A pharmacological therapeutic update. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081568"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/liv.14408","article-title":"Optimization of hepatitis C virus screening strategies by birth cohort in Italy","volume":"40","author":"Kondili","year":"2020","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"Kiser","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/17425255.2015.998997","article-title":"Drug interactions with new hepatitis C oral drugs","volume":"11","author":"Soriano","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kondili, L.A., Gaeta, G.B., Brunetto, M.R., Di Leo, A., Iannone, A., Santantonio, T.A., Giammario, A., Raimondo, G., Filomia, R., and Coppola, C. (2017). Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185728"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_25","first-page":"2","article-title":"Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach","volume":"39","author":"Zignego","year":"2007","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mangia, A., Scaglione, F., Toniutto, P., Pirisi, M., Coppola, N., Di Perri, G., Alvarez Nieto, G., Calabrese, S., Hernandez, C., and Perrone, V. (2021). Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18137144"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/TCRM.S394467","article-title":"Italian real-world analysis of the impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)","volume":"19","author":"Fagiuoli","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_28","first-page":"1239","article-title":"Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: A retrospective observational study","volume":"27","author":"Curry","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_29","first-page":"239","article-title":"Drug-drug interactions in anti-HCV therapy: A comparison among options available in Italy","volume":"27","author":"Cariti","year":"2019","journal-title":"Infez. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_31","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2025, July 21). Determina n. 780\/2017 del 21 Aprile 2017 \u201cEpclusa\u201d, Available online: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2017-04-26&atto.codiceRedazionale=17A02903."},{"key":"ref_32","unstructured":"Agenzia Italiana del Farmaco (AIFA) (2025, July 21). Determina n. 1612\/2017 del 25 Settembre 2017 \u201cMaviret\u201d, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/241028\/Determina_1612-2017_Maviret.pdf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/jpet.119.256966","article-title":"Translation of in vitro transport inhibition studies to clinical drug-drug interactions for glecaprevir and pibrentasvir","volume":"370","author":"Kosloski","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_34","unstructured":"University of Liverpool (2025, July 21). Hepatitis Drug Interactions. (n.d.). Available online: https:\/\/www.hep-druginteractions.org\/interactions\/2640\/all."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.15978","article-title":"Letter: Now is the time to remove complexity from HCV guidelines to ensure that elimination remains a priority","volume":"52","author":"Turnes","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_37","unstructured":"(2025, July 21). Documento di Indirizzo dell\u2019Associazione Italiana per lo Studio del Fegato per l\u2019uso Razionale dei Farmaci Anti-HCV Disponibili in Italia. Available online: https:\/\/www.webaisf.org\/documento-hcv-2020\/."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Andreoni, M., Coppola, N., Crax\u00ec, A., Fagiuoli, S., Gardini, I., Mangia, A., Nava, F.A., and Pasqualetti, P. (2022). Meet-Test-Treat for HCV management: Patients\u2019 and clinicians\u2019 preferences in hospital and drug addiction services in Italy. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-021-06983-y"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40121-015-0058-x","article-title":"A cross-sectional study comparing the frequency of drug interactions after adding simeprevir- or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients","volume":"4","author":"Patel","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40262-016-0373-8","article-title":"Drug-drug interactions between the anti-hepatitis C virus 3D regimen of ombitasvir, paritaprevir\/ritonavir, and dasabuvir and eight commonly used medications in healthy volunteers","volume":"55","author":"Polepally","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","volume":"62","author":"Maasoumy","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Aghemo, A., Persico, M., D\u2019aMbrosio, R., Andreoni, M., Villa, E., Bhagat, A., Gallinaro, V., Gualberti, G., Merolla, R.C.D., and Gasbarrini, A. (2023). Safety and effectiveness of 8 weeks of glecaprevir\/pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280165"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1007\/s12325-022-02158-6","article-title":"Safety and effectiveness using 8 weeks of glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis: The CREST study","volume":"39","author":"Cornberg","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/liv.14829","article-title":"Glecaprevir\/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry","volume":"41","author":"Wedemeyer","year":"2021","journal-title":"Liver Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/liv.14937","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry","volume":"41","author":"Klinker","year":"2021","journal-title":"Liver Int."},{"key":"ref_46","unstructured":"Italian Medicines Agency (AIFA) (2025, July 21). AIFA Registers for Monitoring Anti-HCV Drugs, Available online: https:\/\/www.aifa.gov.it\/en\/aggiornamento-epatite-c."},{"key":"ref_47","first-page":"907","article-title":"PITER Collaborating Investigators Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort","volume":"55","author":"Kondili","year":"2023","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/jcpt.13698","article-title":"Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis","volume":"47","author":"Elshafie","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13722-022-00350-1","article-title":"Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care: Study protocol for the Hepatitis C: Chain of addiction care (CAC) project","volume":"17","author":"Berden","year":"2022","journal-title":"Addict. Sci. Clin. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.18176\/resp.00095","article-title":"Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain","volume":"26","author":"Turnes","year":"2024","journal-title":"Rev. Espa\u00f1ola Sanid. Penit."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","volume":"48","author":"Liu","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_52","first-page":"465","article-title":"Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain","volume":"42","author":"Morillo","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.aohep.2020.09.012","article-title":"Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis","volume":"23","author":"Zhuang","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yamana, Y., Kanda, T., Matsumoto, N., Honda, M., Kumagawa, M., Sasaki, R., Kanezawa, S., Mizutani, T., Yamagami, H., and Masuzaki, R. (2021). Efficacy of Glecaprevir\/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan. J. Clin. Med., 10.","DOI":"10.3390\/jcm10235529"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","article-title":"Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: An open-label phase 3 trial","volume":"54","author":"Takehara","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_56","unstructured":"(2025, July 16). Italian Platform for the Study of Viral Hepatitis Therapies\u2014PITER. Progetto PITER\u2014Slide e Materiali. (n.d.). Available online: https:\/\/www.progettopiter.it\/slide\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40273-018-0733-3","article-title":"Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data","volume":"37","author":"Marcellusi","year":"2019","journal-title":"PharmacoEconomics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s10198-023-01652-0","article-title":"Screening strategy to advance HCV elimination in Italy: A cost-consequence analysis","volume":"25","author":"Marcellusi","year":"2024","journal-title":"Eur. J. Health Econ. HEPAC Health Econ. Prev. Care"},{"key":"ref_59","first-page":"934","article-title":"The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries","volume":"41","author":"Mennini","year":"2021","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:20:17Z","timestamp":1763634017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/11\/1177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pathogens14111177"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14111177","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}